Skip to main content
. 2021 Apr 26;11:8893. doi: 10.1038/s41598-021-88449-4

Figure 4.

Figure 4

Clinical outcomes by IKZF1 alteration. IKZF1 alteration had a prognostic impact on overall survival (OS) and relapse-free survival (RFS) in child B-cell lymphoblastic leukemia/lymphoma (B-ALL), particularly in the good cytogenetic (Gcyto) and intermediate cytogenetic risk (Icyto) groups. Child B-ALL were classified into Gcyto (n = 26) and Icyto (n = 26) groups.